<DOC>
	<DOCNO>NCT02519231</DOCNO>
	<brief_summary>Studies indicate bleed irregularity dysmenorrhea common reason copper IUD method discontinuation . Some evidence suggest non-steroidal anti-inflammatory medication ( NSAIDs ) help improve bleed Cu-IUD use . However , study examine NSAID use TCu380A specifically , evaluate readily available NSAIDs over-the-counter naproxen . For reason , investigator propose pilot trial new TCu380A user complain heavy prolong menstrual bleeding spot 1 month use randomize naproxen placebo take first 7 day menstruation three consecutive cycle , observe one cycle without treatment .</brief_summary>
	<brief_title>Copper IUD Treatment Observation Study</brief_title>
	<detailed_description>The Copper IUD ( Cu-IUD ) widely use IUD world , use United States ( US ) rise . The Cu-IUD consider one effective contraception method , effective permanent sterilization convenience reversible woman decide conceive.2 The Copper 380A ( TCu380A ) Cu-IUD available US ; Cu-IUDs , TCu380A consider effective . Despite increase popularity US , study indicate bleed irregularity dysmenorrhea common reason method discontinuation . Some evidence suggest non-steroidal anti-inflammatory medication ( NSAIDs ) help improve bleed Cu-IUD use . However , study examine NSAID use TCu380A specifically , evaluate readily available NSAIDs over-the-counter naproxen . For reason , investigator propose pilot trial new TCu380A user complain heavy prolong menstrual bleeding spot 1 month use randomize naproxen placebo take first 7 day menstruation three consecutive cycle , observe one cycle without treatment . The number bleeding/spotting day compare use Student t-test . In addition assess well naproxen reduces incidence amount bleeding , investigator also assess use naproxen TCu380A quality life , sexual function , method satisfaction , menstrual pain , adverse event . By measure variable , investigator assess positive negative consequence TCu380A use , ensure harm outweigh benefit .</detailed_description>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Copper</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>• Age ≥ 18 &lt; 49 year . We include wide range age woman age request TCu380A . While recognize woman approach menopause ( median age = 51.4 year ) may change baseline menstruation , trust clinician enrol patient study ensure woman meet inclusion ( i.e. , regular cycle ) exclusion criterion ( i.e. , diagnosis menorrhagia ) . Requesting TCu380A IUD insert contraceptive method . Englishspeaking . Regular menstrual cycle range 2135 day apart . Generally healthy . Willing attend 4 6week followup visit complete survey . Known suspect pregnancy . Contraindications NSAID use . This include underlying heart failure , chronic renal disease , chronic liver disease , peptic ulcer disease , history upper gastrointestinal bleed , allergy NSAIDs . Current regular use NSAID . Unwilling avoid use NSAIDs ( except study medication ) duration study . Current diagnosis menorrhagia , metrorrhagia , symptomatic uterine fibroid , endometrial polyp . Use depot medroxyprogesterone acetate ( DMPA ) levonorgestrelreleasing intrauterine device ( LNG IUD ) within previous 3 month . Postpartum past 4 week . The average day nonbreastfeeding postpartum woman ovulate 25 day birth , indicate menstrual cycle resume 4th postpartum week . Existing medical condition placement TCu380A IUD contraindication accord Centers Disease Control Prevention Medical Eligibility Criteria ( MEC 4 medical condition ; see Appendix A ) . Currently breastfeed . Previous use TCu380A .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>IUD</keyword>
	<keyword>naproxen</keyword>
	<keyword>bleeding</keyword>
</DOC>